Qualification of analytical instruments for use in the pharmaceutical industry: A scientific approach |
| |
Authors: | Surendra K. Bansal Thomas Layloff Ernest D. Bush Marta Hamilton Edward A. Hankinson John S. Landy Stephen Lowes Moheb M. Nasr Paul A. St. Jean Vinod P. Shah |
| |
Affiliation: | 1Hoffmann-La Roche Inc, 07110 Nutley, NJ ;2Management Sciences for Health, 62040 Granite City, IL ;3OSI Pharmaceuticals Inc, 80301 Boulder, CO ;4Pharm Div, Bovis Lend Lease, GU8 6LB Elstead, Surrey UK ;5Aventis, 08807 Bridgewater, NJ ;6Advion BioSciences, 14850 Ithaca, NY ;7Food and Drug Administration, 20852 Rockville, MD ;8Waters Corporation, 01757 Milford, MA |
| |
Abstract: | The purpose of the use of analytical instruments is to generate reliable data. Instrument qualification helps fulfill this purpose. No authoritative guide exists that considers the risk of instrument failure and combines that risk with users' scientific knowledge and ability to use the instrument to deliver reliable and consistent data. In the absence of such a guide, the qualification of analytical instruments has become a subjective and often fruitless document-generating exercise. Taking its cue from the new FDA initiative, “Pharmaceutical GMP's for the 21st Century,” an efficient, science- and risk-based process for AIQ was discussed at a workshop on analytical instrument qualification. This report represents the distillate of deliberations on the complicated issues associated with the various stages of analytical instrument qualification. It emphasizes AIQ's place in the overall process of obtaining quality reliable data from analytical instruments and offers an efficient process for its performance, one that focuses on scientific value rather than on producing documents. Implementing such a process should remove ambiguous interpretations by various groups. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|